in the united states, the 5-year survival rate for cancer overall is currently

Complications from the cancer or treatment.Gene mutations or DNA changes in the cancer cells may predict response to certain chemotherapy regimens.Some of these are patient related and others are specific to the cancer. Many different factors can affect the outcomes of chemotherapy for treatment of leukemia and other blood cancers such as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN) as well as other blood disorders. Other factors that contribute to prognosis Learn more leukemia statistics from the National Cancer Institute.

Acute monocytic leukemia (AML-M5) 5-year survival rate is 23.7%.Acute myeloid leukemia (AML) 5-year survival rate is 31.7%.Chronic myeloid leukemia (CML) 5-year survival rate is 70.6%.Acute lymphocytic leukemia (ALL) 5-year survival rate is 71.3%.Chronic lymphocytic leukemia (CLL) 5-year survival rate is 88%.However, these statistics vary greatly according to the specific subtype of disease: In the United States, overall, 5-year survival among people diagnosed with leukemia is 65%. In addition, the most current national data is from patients diagnosed between 20, which doesn’t reflect the impact of latest treatment advances. Keep in mind that statistics like these are based on large groups of people and cannot predict what might happen with an individual patient. Cancer survival rates are typically discussed in terms of 5-year relative survival, which means the proportion of patients alive five years after their diagnosis.

In the united states, the 5-year survival rate for cancer overall is currently